Evidence map›Paper›PMID 35718423›Full record

ReviewHeart failure clinics2022

Spectrum of National Institutes of Health-Funded Research in Cardio-Oncology: A Basic, Clinical, and Observational Science Perspective.

Bishow B Adhikari, Scarlet Shi, Eileen P Dimond, Nonniekaye Shelburne, Patrice Desvigne-Nickens, Lori M Minasian

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Heart failure clinics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Bishow B AdhikariDivision of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, NIH6705 Rockledge Drive, Room 313-J, MSC 7956, Bethesda, MD 20892-7956, USA. Electronic address: adhikarb@mail.nih.gov.
Scarlet ShiDivision of Cardiovascular Sciences, NHLBI, NIH, 6705 Rockledge Drive, Room 313-H, MSC 7956, Bethesda, MD 20817, USA.
Eileen P DimondDivision of Cancer Prevention, NCI, NIH, 9609 Medical Center Drive Room 5E332, Bethesda, MD 20892, USA.
Nonniekaye ShelburneDivision of Cancer Control and Population Sciences, NCI, NIH, 9609 Medical Center Drive Room 4E110, Bethesda, MD 20892, USA.
Patrice Desvigne-NickensDivision of Cardiovascular Sciences, NHLBI, NIH, 6705 One Rockledge Drive, Room 312-B2, Bethesda, MD 20892-7940, USA.
Lori M MinasianDivision of Cancer Prevention, NCI, NIH, 9609 Medical Center Dr. Room 5E342, Bethesda, MD 20892, USA.
Center for Cancer Research · USNational Heart Lung and Blood Institute · USNational Institutes of Health · US

Funding

Intramural NIH HHS Z99 HL999999
6 · The paper itself

Abstract

Advances in cancer treatments have led to nearly 17 million survivors in the US today. Cardiovascular complications attributed to cancer treatments are the leading cause of morbidity and mortality in cancer survivors. In response, NCI and NHLBI held 2 workshops and issued funding opportunities to strengthen research on cardiotoxicity. A representative portfolio of NIH grants categorizing basic, interventional, and observational projects is presented. Compared with anthracyclines, research on radiation therapy and newer treatments is underrepresented. Multidisciplinary collaborative research that considers the cardiotoxicity stage and optimizes the balance between cardiovascular risk and cancer-treatment benefit might support continued improvements in cancer outcomes.

Indexed as

CardiotoxicityNeoplasmsAnthracyclinesHumansMedical OncologyNational Institutes of Health (U.S.)United StatesAnthracyclinesCancer therapyCancer treatmentCardiac toxicityCardiotoxicityCardiovascular complicationsCardiovascular toxicityChemotherapyRadiation injury

Identifiers

PMID35718423
PMCPMC9328446
OpenAlexW4283018399

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.